Incretin receptor agonists produce clinically meaningful weight loss in type 2 diabetes patients while simultaneously improving glycemic control, cardiovascular outcomes, and heart failure symptoms. However, the weight reduction consistently falls short of results seen in non-diabetic obesity patients, attributed to impaired metabolic flexibility—the reduced ability to switch between fuel sources efficiently. This metabolic rigidity in diabetes represents a fundamental physiological barrier rather than treatment failure. The finding reframes obesity treatment expectations for the 37 million Americans with type 2 diabetes. Rather than chasing arbitrary weight-loss percentages, clinicians should focus on the constellation of metabolic improvements these medications deliver: organ protection, functional capacity gains, and symptom relief. This paradigm shift is particularly relevant as obesity drugs become mainstream treatments. The research reinforces that diabetes fundamentally alters metabolic machinery, requiring personalized treatment goals that prioritize health outcomes over scale numbers. For patients and providers, this evidence validates a more nuanced approach to success metrics in diabetes care.